Mizuho analyst Uy Ear reiterated an Outperform rating and $19.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

TD Cowen Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT)August 15, 2024 9:21 AM CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 9:00 PM Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9cAugust 14, 2024 4:20 PM Form 10-Q Arcutis Biotherapeutics, For: Jun 30August 14, 2024 4:13 PM Form 8-K Arcutis Biotherapeutics, For: Aug 14August 14, 2024 4:04 PM